Navigation Links
Organon's Sugammadex Demonstrated a 9-12 Times Faster Recovery in,Phase III Pivotal Trial as Compared to Neostigmine

OSS, The Netherlands, June 11, 2007 /PRNewswire/ -- Sugammadex - the novel selective relaxant binding agent (SRBA) being developed by Organon, the human healthcare business unit of Akzo Nobel - demonstrated in a Phase III pivotal trial a 9-12 times faster reversal of neuromuscular blockade as compared to neostigmine, without evidence of post operative residual curarization (PORC) or re-occurrence of muscle relaxation.(1),(2) The results of this pivotal Aurora trial were presented today at the 14th annual Euroanaesthesia 2007 congress in Munich, Germany.

The Aurora trial compared the efficacy of sugammadex and neostigmine for the reversal of shallow neuromuscular blockade induced by single or multiple doses of either rocuronium (Esmeron(R)/Zemuron(R)) or vecuronium (Norcuron(R)).

"Sugammadex has shown a rapid and complete reversal in this pivotal trial without evidence of PORC or re-occurrence of neuromuscular blockade. Effective reversal is critically important to ensure that patients recover quickly and completely, without the risk of breathing difficulties," commented one of the lead investigators involved in the Aurora trial, Professor M. Blobner from the Klinik fur Anasthesiologie der Technischen Universitat Munchen, Germany.

Reversal agents are used during general anesthesia to reverse the effects of muscle relaxants, also called neuromuscular blocking agents (NMBAs). Reversal of neuromuscular blockade is used to reduce the risk of PORC or re-occurrence of muscle relaxation.

Phase III Trial Overview

The international, randomised, multicenter, parallel-group Aurora trial was conducted at 13 European centers and enrolled 198 patients. In the trial sugammadex was administered at reappearance of T2 and achieved significantly faster recovery of the T4/T1 ratio to 0.9 compared with neostigmine. Median time to recovery was 1.4 minutes (0.9-5.4; p<0.0001) for sugammadex versus 17
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Organons Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial Compared to Neostigmine
2. Organons Asenapine Effective in a Phase III Study for the Treatment of Bipolar I Disorder; Results Unveiled at 2007 APA Meeting
3. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
4. Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone
5. Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone
6. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
7. Study Demonstrated Rozerem (ramelteon) Does Not Affect Middle-of-the-Night Balance in Older Adults with Insomnia
8. Repros Reports That Proellex Has Demonstrated Superior Efficacy and Safety in Endometriosis When Compared to Standard of Drug Care
9. Trexima (Sumatriptan/Naproxen Sodium) Demonstrated Migraine-Free Response Across Multiple Attacks
10. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
11. Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
Post Your Comments:
(Date:5/24/2013)... -- Solta Medical, Inc. (NASDAQ: SLTM ), a ... Edward W. Knowlton has resigned as ... Dr. Knowlton is the founder of Thermage, the predecessor company ... 1996. "On behalf of the entire Board of ... to thank Ed for his tireless dedication to our company ...
(Date:5/24/2013)... LOS ANGELES , May 24, 2013  An ... gathered on Saturday, May 18, in Santa ... findings on new lung-sparing therapies for MPM, a rare ... and commonly affects the pleura, the lining of the ... Heart, Lung and Blood Institute, the 3rd Annual International ...
(Date:5/24/2013)... LOVELAND, Colo. , May 24, 2013  Heska Corporation ... veterinary diagnostic and specialty products, announced today that Dr. ... executive officer, and Jason Napolitano , executive ... Second Annual Marcum MicroCap Conference, which is being held May ... at the Grand Hyatt Hotel. The Company,s ...
Breaking Medicine Technology:Dr. Edward W. Knowlton Resigns as a Director of Solta Medical, Inc. 2International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma 2International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma 3Heska Corporation To Present At The Second Annual Marcum LLP MicroCap Conference 2
... Scientific advances at The Scripps Research Institute ... Benlysta® (belimumab), approved today by the U.S. Food and Drug ... is the first in a new class of pharmaceuticals that ... "I am deeply gratified that our scientific findings have ...
... March 9, 2011 Gentiva Health Services, Inc. (Nasdaq: ... the Barclays Capital 2011 Global Healthcare Conference in Miami, Florida ... at the Barclays Capital High Yield Bond and Syndicated Loan ... March 24, 2011. The presentations will be available ...
Cached Medicine Technology:New Lupus Drug Results From Scripps Research Technology 2New Lupus Drug Results From Scripps Research Technology 3New Lupus Drug Results From Scripps Research Technology 4Gentiva® Health Services to Present at Upcoming Investor Conferences 2Gentiva® Health Services to Present at Upcoming Investor Conferences 3
(Date:5/24/2013)... News) -- The number of U.S. patients admitted ... in an emergency room has increased by nearly ... study, conducted by researchers at the George Washington ... in Washington, D.C., found that patients wait five ... being admitted to the ICU. The researchers said ...
(Date:5/24/2013)... in five parents think they have little control over ... drug use, a new U.S. government survey finds. ... and Mental Health Services Administration (SAMHSA), since new research ... influential forces helping to shape their child,s views on ... that parents can make an enormous difference in influencing ...
(Date:5/24/2013)... Two out of five medical students have an unconscious ... The study authors, from Wake Forest Baptist Medical Center, ... the treatment of obesity. They concluded that teaching medical ... care for the millions of Americans who are overweight ... the doctor-patient relationship, and even a patient,s willingness or ...
(Date:5/24/2013)... 2013 The SunglassFIX Photo Contest ... all while learning how to make their sunglasses, ... Contestants only need to upload pictures of themselves, ... The Sunglass Fix on Facebook in order to ... largest lens replacement online store . ...
(Date:5/24/2013)... 2013, Paris, France: Routinely measuring fractional flow reserve ... for diagnosis of chest pain leads to significant ... patients, according to results from a study reported ... pressure wire assessment influence management strategy at coronary ... designed to assess whether routine assessment of FFR ...
Breaking Medicine News(10 mins):Health News:Sharp Rise in ICU Admissions From U.S. Emergency Rooms 2Health News:Parents Underestimate Influence Over Teens' Substance Abuse: Survey 2Health News:Many Medical Students Have Anti-Fat Bias, Study Finds 2Health News:Break the Sunglass Mold – Reuse 'Em, Don’t Toss 'Em then Enter the SunglassFIX Photo Contest to Win 2Health News:Diagnostic coronary angiography: Functional flow reserve changes decisions in 25 percent of cases 2
... , , NEW YORK, Aug. 10 ... exclusive commercialisation rights to Daxas((R)) in the United States in treatment of symptomatic ... plus significant milestones and royalties , Daxas filed for ... , Access to Forest Laboratories, 2,700-strong US sales force ...
... , , UNION ... ABAX ), a medical products company manufacturing point-of-care blood analysis ... the appointment of Brenton Hanlon to the position of vice ... Mr. Hanlon, a member of the Abaxis Board of Directors ...
... BETHESDA, Md., Aug. 10 /PRNewswire-Asia/ -- Chindex International, ... American provider of Western,healthcare products and services in the ... into two new exclusive, multi-year distribution,agreements for China with ... Biotest AG, based in Dreieich, Germany (SDAX: BIO3), ...
... ... selling author Mary Shomon , ... Joplin, MO (PRWEB) August 10, 2009 -- MyMedLab, Inc. today announced the ... Medicine" series. The author chosen to pilot the first release is nationally-known thyroid patient ...
... ... ... 2009 -- Tucson, Arizona is home to a dense Hispanic population. In recognition of ... spreading the word throughout the local Hispanic community that colorectal pre-screening can save lives., ...
... the place of amputation for bone and soft tissue sarcomas ... much or even any additional benefit to patients according to ... 2009 issue of Cancer , a peer-reviewed journal of ... rethink the pros and cons of limb-sparing surgery and amputation. ...
Cached Medicine News:Health News:Nycomed and Forest Laboratories to Collaborate on US Commercialisation of Daxas(R) in COPD 2Health News:Nycomed and Forest Laboratories to Collaborate on US Commercialisation of Daxas(R) in COPD 3Health News:Nycomed and Forest Laboratories to Collaborate on US Commercialisation of Daxas(R) in COPD 4Health News:Nycomed and Forest Laboratories to Collaborate on US Commercialisation of Daxas(R) in COPD 5Health News:ABAXIS Announces Appointment of Brenton Hanlon to Vice President of North American Medical Sales and Marketing 2Health News:ABAXIS Announces Appointment of Brenton Hanlon to Vice President of North American Medical Sales and Marketing 3Health News:Chindex International Announces Exclusive Distribution Agreements in China for Leading Clinical Chemistry and Aesthetic Laser Products 2Health News:Chindex International Announces Exclusive Distribution Agreements in China for Leading Clinical Chemistry and Aesthetic Laser Products 3Health News:Chindex International Announces Exclusive Distribution Agreements in China for Leading Clinical Chemistry and Aesthetic Laser Products 4Health News:MyMedLab Releases First Offer in Its Unique Personalized Medicine Series 2Health News:MyMedLab Releases First Offer in Its Unique Personalized Medicine Series 3Health News:Hispanics at High Risk for Colorectal Cancer 2Health News:Hispanics at High Risk for Colorectal Cancer 3Health News:Limb-sparing surgery may not provide better quality of life than amputation for bone cancer patients 2
Rees bayonet forceps, standard, 5-1/2", TC....
Medpor Encophthalmos Wedge mimics the contour of the orbital floor and provides volume to restore the orbit to its normal shape and size....
... Medpor Channel Implants, designed ... provide the surgeon with an ... orbital wall and floor blowout ... channels for placement of one ...
Medpor Complete Orbit are designed to replace non load bearing bony structures in the orbital area....
Medicine Products: